|
|||||
|
|
Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials |
|
| Authors: | Carine Beysen DPhil Patricia Schroeder PhD Eric Wu PhD Julie Brevard MPH Maria Ribadeneira PhD Wei Lu PhD Kiran Dole PharmD Terry O'Reilly MD Linda Morrow MD Marcus Hompesch MD Marc K. Hellerstein MD Kelvin Li PhD Lars Johansson PhD Patrick F. Kelly MD |
| Affiliation: | 1. FluxBio, San Mateo, California;2. Forma Therapeutics, Watertown, Massachusetts;3. Celerion, Tempe, Arizona;4. ProSciento Inc, Chula Vista, California;5. Department of Nutritional Sciences and Toxicology, University of California, Berkeley, Berkeley, California;6. Antaros Medical, Mölndal, Sweden |
| Abstract: | |
| Keywords: | drug development drug mechanism fatty liver disease pharmacodynamics phase I−II study randomized trial |